RAD 140

Drug Profile

RAD 140

Alternative Names: RAD-140

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Radius
  • Developer Radius; Radius Health Inc.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • No development reported Muscular atrophy; Osteoporosis

Most Recent Events

  • 29 Sep 2017 Phase-I clinical trials in Breast cancer (Metastatic disease) in USA (PO) (NCT03088527)
  • 03 Aug 2017 US FDA accepted an IND application submitted by Radius Health for Breast cancer
  • 24 Feb 2017 Radius Health has patent protection for RAD 140 in USA, Australia, Canada, Europe, Japan and Mexico (Radius Health's form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top